Full-Time

Scientist/Senior Scientist

Functional Genomics

Posted on 4/8/2025

NewLimit

NewLimit

51-200 employees

Develops epigenetic medicines to extend healthspan

No salary listed

San Bruno, CA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Ph.D. in molecular biology, cell biology, or a related field **or** equivalent industry experience (5+ years)
  • Experience with functional genomics approaches for pooled or arrayed screening (e.g. one of: CRISPR-Cas pooled fitness screens, gene expression perturbation profiling, Perturb/CROP-seq, or similar methods)
  • Experience with molecular cloning, next-generation sequencing, and associated molecular biology methods
  • Experience with *in vitro* and *in vivo* transgenic delivery methods for mammalian cells (at least one of: lentivirus, AAV, AdV, transposition systems, lipid nanoparticles, or similar)
Responsibilities
  • Run the largest reprogramming screens in the world in collaboration with our Single Cell Genomics and Predictive Modeling teams
  • Develop methods for the construction, delivery, and control of epigenetic reprogramming payloads for single cell screens in primary mammalian cells
  • Build and deploy molecular tools at a massive scale
  • Design and implement functional genomics screens to measure the effect of epigenetic reprogramming on the molecular and functional state of primary mammalian cells
  • Contribute to the design and formulation of therapeutic molecules (e.g. mRNA synthesis and optimization, lipid nanoparticle formulation)
Desired Qualifications
  • Experience with epigenetic reprogramming methods using transcription factors for cell fate engineering or CRISPR-Cas tools for targeted epigenetic editing
  • Experience working with primary cells and tissue samples
  • Experience with single cell genomics methods
  • Strong Python programming and Unix workflow management skills
  • Therapeutics development experience

NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.

Company Size

51-200

Company Stage

Series C

Total Funding

$650M

Headquarters

South San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • $435 million Series C funds clinical entry and computational expansion.
  • Lead liver program targets alcohol-related liver disease with clear translational endpoints.
  • Platform expansion into immune and vascular cells broadens addressable aging indications.

What critics are saying

  • First-in-human liver reprogramming data arrive late, extending validation uncertainty.
  • Epigenetic reprogramming can trigger tumorigenicity or permanent cell-identity loss.
  • Lipid nanoparticle RNA delivery can fail before biology reaches human cells.

What makes NewLimit unique

  • AI-guided transcription factor screening compresses reprogramming discovery cycles.
  • Lead liver program uses lipid nanoparticle RNA medicines for transient expression.
  • Single-cell genomics and functional assays form an iterative closed-loop platform.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at NewLimit who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Intellectia.AI
Jan 6th, 2026
Coinbase CEO Armstrong's NewLimit raises $45M at $1.62B valuation for anti-aging research

NewLimit, an anti-aging startup founded in 2021 by Coinbase CEO Brian Armstrong, has raised $45 million in new funding, valuing the company at $1.62 billion. The round comes just five months after its Series B, demonstrating rapid growth and strong investor confidence. The company focuses on extending human healthspan by treating age-related diseases. The fresh capital will support groundwork for future clinical studies to advance its technological capabilities. Competition in the longevity sector is intensifying, with OpenAI CEO Sam Altman investing $180 million in rival Retro Biosciences. Despite a 2025 downturn in anti-aging research stocks, NewLimit's successful funding round highlights investor belief in the sector's long-term potential and suggests continued capital flow into this emerging market.

NewLimit
Oct 22nd, 2025
NewLimit has raised an additional $45M from Lilly, Duke University, Section 32, & Abstract on a $1.62B cap

Five months after closing our Series B, NewLimit has raised an additional $45M from Eli Lilly and Company, Duke Management Co, Section 32, and others on a $1.62B cap.

Endpoints News
Oct 20th, 2025
NewLimit Raises $45M with Eli Lilly

NewLimit, an anti-aging biotech startup co-founded by a cryptocurrency billionaire, has raised $45 million from new investors, including Eli Lilly. This funding positions NewLimit to potentially become biotech's latest unicorn.

TradingView
May 15th, 2025
NewLimit Raises $129.8M in Equity Financing

NewLimit has successfully raised $129.8 million in equity financing from a total offering amount of $130 million.

NewLimit
May 7th, 2025
NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others

NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming

INACTIVE